Queen Mary University of London
5 days ago
Fully Funded PhD in Resomelagon for Rheumatoid Arthritis and Cardiovascular Comorbidities Queen Mary University of London in United Kingdom
Degree Level
PhD
Field of study
Pharmacology
Funding
Fully funded Doctoral Candidate position within HARPNET, a Marie Skłodowska-Curie Actions Doctoral Network. Funding includes an employment contract plus the applicable MSCA living and mobility allowances; family allowances may apply where eligible.
Deadline
Oct 1, 2026
Country
United Kingdom
University
Queen Mary University of London
How do I apply for this?
Sign in for free to reveal details, requirements, and source links.
Apply for this position
Keywords
Suggested positions
About this position
PhD opportunity at Queen Mary University of London / William Harvey Research Institute in resomelagon, rheumatoid arthritis, and cardiovascular comorbidities.
This project investigates how the clinical-stage melanocortin receptor agonist resomelagon may reduce inflammatory arthritis while also improving cardiovascular outcomes linked to rheumatoid arthritis. The research will examine anti-arthritic effects, systemic immune responses, immune-cell trafficking, macrophage reprogramming, resolution mechanisms, and biomarkers associated with therapeutic response and cardiovascular benefit.
Students will gain hands-on training in translational pharmacology, experimental arthritis and cardiovascular models, macrophage phenotyping, specialised pro-resolving mediator analysis, biomarker development, and PK/PD-informed drug-development strategies. The project is designed for candidates interested in moving resolution pharmacology toward patient benefit.
Eligible applicants should have, or expect to obtain by October 2026, a Master’s degree or equivalent that allows doctoral enrolment at QMUL. A background in pharmacology, immunology, clinical science, biotechnology, or translational medicine is preferred. Applicants must be proficient in English and meet the MSCA mobility rule (not having lived or carried out their main activity in the UK for more than 12 months in the previous 36 months).
This is a fully funded Doctoral Candidate position in the HARPNET Marie Skłodowska-Curie Actions Doctoral Network, with an employment contract and applicable living and mobility allowances; family allowances may apply if eligible.
Apply via the HARPNET recruitment portal and submit one central application, ranking up to three project choices. Deadline shown on the listing: 2026-10-01.
Funding details
Fully funded Doctoral Candidate position within HARPNET, a Marie Skłodowska-Curie Actions Doctoral Network. Funding includes an employment contract plus the applicable MSCA living and mobility allowances; family allowances may apply where eligible.
What's required
Applicants should have or expect to obtain by October 2026 a Master’s degree or equivalent qualification that permits doctoral enrolment at Queen Mary University of London. A background in pharmacology, immunology, clinical science, biotechnology or translational medicine is preferred, along with enthusiasm for drug development and evaluation of clinical-stage therapeutics. Applicants must not already hold a doctoral degree, must be proficient in English, and must satisfy the MSCA mobility rule by not having resided or carried out their principal activity in the United Kingdom for more than 12 months in the 36 months immediately preceding recruitment.
How to apply
Visit the HARPNET recruitment page for full details and submit one central HARPNET application. You may rank up to three project choices. For application queries, contact [email protected].
More information can be found here
Ask ApplyKite AI
How do I apply for this?
Sign in for free to reveal details, requirements, and source links.